| Year |
Citation |
Score |
| 2021 |
Brown M, Zhang G, Stevenson K, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon J, Varn F, Verhaak R, Zhao J, Friedman A, ... ... Sampson J, et al. BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM Neuro-Oncology. 23: vi14-vi15. DOI: 10.1093/neuonc/noab196.051 |
0.31 |
|
| 2020 |
Brady M, Raghavan R, Sampson J. Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. Pharmaceutics. 12. PMID 32967184 DOI: 10.3390/Pharmaceutics12090895 |
0.303 |
|
| 2020 |
Batich KA, Mitchell DA, Healy P, Herndon JE, Sampson JH. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32719000 DOI: 10.1158/1078-0432.CCR-20-1082 |
0.3 |
|
| 2020 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, Reynolds P, Monie DD, Johnson AJ, Coffey M, Young SL, ... Sampson J, et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nature Communications. 11: 3187. PMID 32581235 DOI: 10.1038/S41467-020-17011-Z |
0.324 |
|
| 2020 |
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, ... Sampson J, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 32437507 DOI: 10.1001/Jamaoncol.2020.1024 |
0.338 |
|
| 2020 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Landi D, Khasraw M, Threatt S, Bullock C, Herndon J, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, et al. CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG) Neuro-Oncology. 22: ii38-ii38. DOI: 10.1093/neuonc/noaa215.157 |
0.327 |
|
| 2020 |
Sampson J, Achrol A, Aghi M, Bankiewiecz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson B, Floyd J, Han S, Kesari S, Merchant F, et al. CTIM-13. CLINICAL EFFICACY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, IN RECURRENT GBM DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) Neuro-Oncology. 22: ii35-ii35. DOI: 10.1093/neuonc/noaa215.147 |
0.315 |
|
| 2019 |
Desjardins A, Gromeier M, Herndon JE, Randazzo D, Threatt S, Lipp ES, Miller ES, Jackman J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Peters KB, Johnson MO, Sampson JH, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial. Journal of Clinical Oncology. 37: 2060-2060. DOI: 10.1200/Jco.2019.37.15_Suppl.2060 |
0.31 |
|
| 2019 |
Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Sampson J, Perez LS, Vile R. Abstract A029: Unexpected antagonism between oncolytic virus derived type I interferon and EGFRvIII CAR T-cells Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A029 |
0.326 |
|
| 2019 |
Landi D, Archer G, Driscoll T, Herndon J, Sampson J, Ashley D. Pdct-10. Feasibility Of Leukapheresis For Harvesting Monocytes And Generating Autologous Dendritic Cell Vaccines In Children With Malignant Brain Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.772 |
0.333 |
|
| 2019 |
Schaller T, Foster M, Spasojevic I, Gedeon P, Sanchez-Perez L, Sampson J. EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA Neuro-Oncology. 21: vi84-vi84. DOI: 10.1093/Neuonc/Noz175.343 |
0.375 |
|
| 2019 |
Weller M, Reardon D, Brandes A, Sampson J, Mulholland P, Wick A, Baehring J, Ahluwalia M, Roth P, Bähr O, Phuphanich S, Sepulveda J, Souza Pd, Sahebjam S, Potter V, et al. Atim-47. Nivolumab Vs Bevacizumab In Patients With Recurrent Glioblastoma: Exploratory Analysis Of Mgmt Methylation Status And Baseline Corticosteroid Use Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.045 |
0.305 |
|
| 2019 |
Peters K, Congdon K, Archer G, Woodring S, Jaggers D, Lipp E, Healy P, Herndon J, Soher B, Vlahovic G, Johnson M, Randazzo D, Desjardins A, Friedman H, Friedman A, ... ... Sampson J, et al. ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.030 |
0.389 |
|
| 2019 |
Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, ... ... Sampson J, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026 |
0.416 |
|
| 2019 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Threatt S, Bullock C, Jackman J, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 21: vi6-vi6. DOI: 10.1093/Neuonc/Noz175.023 |
0.364 |
|
| 2018 |
Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE, Healy P, Archer GE, Choi BD, Fecci PE, ... Sampson JH, et al. Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. Oncoimmunology. 7: e1434464. PMID 29872570 DOI: 10.1080/2162402X.2018.1434464 |
0.347 |
|
| 2018 |
Congdon KL, Sanchez-Perez LA, Sampson JH. Abstract CN02-02: Immunotherapy for central nervous system cancers Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Cn02-02 |
0.323 |
|
| 2018 |
Batich K, Ashley D, Archer G, Sanchez-Perez L, Norberg P, Congdon K, Herndon J, McSherry F, Gemberling S, Hesler R, Jaggers D, Van R, Parker J, Peters K, Desjardins A, ... ... Sampson J, et al. RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL Neuro-Oncology. 20: vi234-vi234. DOI: 10.1093/Neuonc/Noy148.972 |
0.319 |
|
| 2018 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Thomas L, Threatt S, Bullock C, Herndon J, Boulton S, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, et al. ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 20: vi9-vi9. DOI: 10.1093/Neuonc/Noy148.031 |
0.333 |
|
| 2018 |
Gururangan S, Grant G, Driscoll T, Archer G, Herndon J, Friedman H, Kurtzberg J, Bigner D, Sampson J, Mitchell D. IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.343 |
0.387 |
|
| 2018 |
Schuelke M, Evgin L, Wongthida P, Thompson J, Kottke T, Sanchez-Perez L, Sampson J, Vile R. IMMU-12. T-CELL THERAPIES DEMONSTRATE EFFICACY WITHOUT TOXICITY IN IMMUNOCOMPETENT MODELS OF BRAINSTEM TUMORS Neuro-Oncology. 20: i101-i101. DOI: 10.1093/Neuonc/Noy059.328 |
0.357 |
|
| 2018 |
Bexon MF, Achrol A, Bankiewicz K, Brenner A, Butowski N, Kesari S, Merchant F, Merchant R, Randazzo D, Vogelbaum M, Zabek M, Sampson J. Understanding biological activity, tumor response and pseudoprogression in a phase-IIb study of MDNA55 in adults with recurrent or progressive glioblastoma (GB). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy273.368 |
0.339 |
|
| 2017 |
Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, Souza Pd, Ahluwalia MS, Lim M, Vlahovic G, Sampson J. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143 Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.071 |
0.345 |
|
| 2017 |
Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, Sahebjam S, Lim M, Zwirtes R, Sampson J. OS07.3 Nivolumab in Combination With Radiotherapy With or Without Temozolomide in Patients With Newly Diagnosed Glioblastoma: Updated Results From CheckMate 143 Neuro-Oncology. 19: iii13-iii13. DOI: 10.1093/Neuonc/Nox036.044 |
0.363 |
|
| 2017 |
Wang C, Sun W, Kirkpatrick JP, Sampson J, Chang Z, Yin FF. Assessment of Concurrent Stereotactic Radiosurgery and Bevacizumab Treatment of Recurrent Malignant Gliomas Using Multiparametric MRI Imaging and Radiomics Analysis International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.2367 |
0.321 |
|
| 2016 |
Farber SH, Elsamadicy AA, Atik F, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion On Drug Safety. PMID 27989218 DOI: 10.1080/14740338.2017.1273898 |
0.305 |
|
| 2016 |
Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls. Journal of Clinical Oncology. 34: 2061-2061. DOI: 10.1200/Jco.2016.34.15_Suppl.2061 |
0.323 |
|
| 2016 |
Desjardins A, Randazzo D, Chandramohan V, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, Healy P, Lipp E, Friedman A, Friedman H, Bigner D. ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 18: vi21-vi22. DOI: 10.1093/Neuonc/Now212.083 |
0.339 |
|
| 2016 |
Omuro A, Vlahovic G, Baehring J, Butowski NA, Reardon DA, Cloughesy T, Sahebjam S, Lim M, Strauss L, Latek R, Zwirtes R, Paliwal P, Harbison C, Sampson J. ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143 Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.081 |
0.343 |
|
| 2015 |
Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, ... ... Sampson JH, et al. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 62: 198-199. PMID 26181953 DOI: 10.1227/01.Neu.0000467069.86811.3F |
0.301 |
|
| 2015 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374 |
0.376 |
|
| 2015 |
Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH. Immunotherapy for malignant glioma. Surgical Neurology International. 6: S68-77. PMID 25722935 DOI: 10.4103/2152-7806.151341 |
0.312 |
|
| 2015 |
Boyle J, McSherry F, Herndon J, Desjardins A, Sampson J, Peters K, Chino J, Allen K, Cabrera A, Kim G, Friedman H, Kirkpatrick J. Rtrb-04Stereotactic Radiosurgery For Recurrent High-Grade Gliomas: Patient Selection And The Role Of Bevacizumab Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov231.04 |
0.363 |
|
| 2015 |
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W, Ellingson B, Hashimoto N, Pollack I, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, ... ... Sampson J, et al. NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov225.56 |
0.397 |
|
| 2015 |
Omuro A, Baehring J, Sahebjam S, Vlahovic G, Voloschin A, Young R, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Sampson J, Reardon DA. NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143) Neuro-Oncology. 17: v157.1-v157. DOI: 10.1093/Neuonc/Nov225.18 |
0.371 |
|
| 2015 |
Ramkissoon S, Sampson J, Vlahovic G, Sahebjam S, Omuro A, Baehring J, Latek R, Vandeloise E, Coric V, Cloughesy T, Lim M, Reardon D, Ligon K. NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143 Neuro-Oncology. 17: v156.4-v157. DOI: 10.1093/Neuonc/Nov225.17 |
0.406 |
|
| 2015 |
Sahebjam S, Omuro A, Baehring J, Sampson J, Vlahovic G, Voloschin A, Hayes W, Latek R, Coric V, Cloughesy T, Lim M, Reardon DA. NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717) Neuro-Oncology. 17: v156.3-v156. DOI: 10.1093/Neuonc/Nov225.16 |
0.374 |
|
| 2015 |
Sampson J, Omuro A, Vlahovic G, Sahebjam S, Baehring J, Hafler DA, Voloschin A, Simon J, Latek R, Coric V, Cloughesy T, Lim M, Reardon D. IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143 Neuro-Oncology. 17: v107.3-v107. DOI: 10.1093/Neuonc/Nov218.03 |
0.426 |
|
| 2015 |
Pham C, Flores C, Yang C, Sayour E, Pei Y, Moore C, McLendon R, Huang J, Sampson J, Wechsler-Reya R, Mitchell D. IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA Neuro-Oncology. 17: v118.3-v118. DOI: 10.1093/Neuonc/Nov217.24 |
0.355 |
|
| 2015 |
Lowther DE, Weinhold K, Reap E, Vlahovic G, Omuro A, Sahebjam S, Baehring J, Voloschin A, Cloughesy T, Lim M, Coric V, Latek R, Simon J, Lerner B, Raddassi K, ... ... Sampson J, et al. CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143 Neuro-Oncology. 17: v70.2-v70. DOI: 10.1093/Neuonc/Nov211.06 |
0.422 |
|
| 2015 |
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Atct-13Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression: A Phase Ii Trial Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.13 |
0.371 |
|
| 2014 |
Swartz AM, Li QJ, Sampson JH. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy. 6: 679-90. PMID 25186601 DOI: 10.2217/Imt.14.21 |
0.326 |
|
| 2014 |
Mowery Y, Wright A, Desjardins A, Peters K, Ranjan T, Vlahovic G, Friedman H, Zomorodi A, Kaylie D, Adogwa O, Nimjee S, Sperduto W, Chagoya G, Fatemi P, McLendon R, ... ... Sampson J, et al. MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Neuro-Oncology. 16: v130-v131. DOI: 10.1093/Neuonc/Nou260.18 |
0.382 |
|
| 2014 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner D, Sampson J, Mitchell D. IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.8 |
0.396 |
|
| 2014 |
Vlahovic G, Archer G, Lally-Goss D, Reap E, Batich K, Desjardins A, Peters K, Ranjan T, Healy P, Herndon J, Friedman A, Friedman H, Bigner D, Sampson J. IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.32 |
0.393 |
|
| 2014 |
Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G, Lukas R, Desjardins A, Ashby L, Duic JP, Aneiro L, Hawthorne T, Green J, Yellin M, Davis T, ... Sampson J, et al. IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou258.28 |
0.404 |
|
| 2014 |
Kirkpatrick J, Wang Z, Sampson J, McSherry F, Herndon J, Allen K, Duffy E, Chang Z, Hoang J, Kelsey C, Yoo D, Cabrera A, Yin F. Bm-17Final Results Of A Randomized Trial To Identify The Optimal Planning Target Volume In Image-Guided Stereotactic Radiosurgery Of Brain Metastases Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou240.17 |
0.352 |
|
| 2014 |
Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. At-22Phase Ii Trial Of Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.22 |
0.377 |
|
| 2014 |
Desjardins A, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Lipp E, Friedman A, Friedman H, Bigner D, Gromeier M. AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.21 |
0.377 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-20Single Institution Retrospective Review Of Performance Status And Corticosteroid Use In Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated On Bevacizumab (Bev) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.20 |
0.34 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Boulton S, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-19Single Institution Retrospective Comparison Of Glioblastoma (Gbm) Patients (Pts) Initiated On Bevacizumab (Bev) Before Versus After Recurrence In Clinical Practice Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.19 |
0.305 |
|
| 2014 |
Gromeier M, Dobrikova E, Dobrikov M, Brown M, Bryant J, Threatt S, Boulton S, Carter K, Herndon J, Desjardins A, Friedman H, Sampson J, Friedman A, Bigner D. ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA Neuro-Oncology. 16: iii41-iii41. DOI: 10.1093/Neuonc/Nou208.69 |
0.353 |
|
| 2014 |
Sampson J, Mitchell DA, Batich KA, Snyder D, Xie W, Reap E, Cui X, Sanchez-Perez L, Archer GE, Nair SK, Gunn MD. RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.63 |
0.343 |
|
| 2013 |
Gedeon PC, Choi BD, Sampson JH, Bigner DD. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. Drugs of the Future. 38: 147-155. PMID 25663738 DOI: 10.1358/Dof.2013.038.03.1933992 |
0.324 |
|
| 2013 |
Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. The Journal of Clinical Investigation. 123: 3135-45. PMID 23934126 DOI: 10.1172/Jci67544 |
0.343 |
|
| 2013 |
Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. International Journal of Radiation Oncology, Biology, Physics. 86: 873-9. PMID 23725997 DOI: 10.1016/J.Ijrobp.2013.04.029 |
0.331 |
|
| 2013 |
Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma. Journal of Clinical Oncology. 31: 2094-2094. DOI: 10.1200/JCO.2013.31.15_SUPPL.2094 |
0.33 |
|
| 2012 |
Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clinical & Developmental Immunology. 2012: 480429. PMID 22400035 DOI: 10.1155/2012/480429 |
0.302 |
|
| 2012 |
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107: 155-64. PMID 21986722 DOI: 10.1007/S11060-011-0722-2 |
0.306 |
|
| 2012 |
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106: 409-15. PMID 21938530 DOI: 10.1007/S11060-011-0687-1 |
0.315 |
|
| 2012 |
Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 82: 2018-24. PMID 21489708 DOI: 10.1016/J.Ijrobp.2010.12.074 |
0.309 |
|
| 2012 |
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 82: 58-66. PMID 21036490 DOI: 10.1016/J.Ijrobp.2010.08.058 |
0.312 |
|
| 2012 |
Desjardins A, Vredenburgh JJ, Peters KB, Threatt S, Herndon JE, Sampson JH, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. Journal of Clinical Oncology. 30: 2095-2095. DOI: 10.1200/Jco.2012.30.15_Suppl.2095 |
0.32 |
|
| 2012 |
Dannull J, Haley NR, Archer G, Nair S, Rosa ND, Selim M, Tyler DS, Sampson J, Pruitt SK. Abstract 5373: Altering the composition of the proteasome of melanoma antigen RNA-transfected dendritic cells enhances vaccination-induced anti-melanoma immunity: results of a Phase I trial Cancer Research. 72: 5373-5373. DOI: 10.1158/1538-7445.Am2012-5373 |
0.347 |
|
| 2012 |
Lewis S, Vredenburgh J, Desjardins A, Peters K, Green S, Hood R, Yang Y, Sampson J, Wang Z, Kirkpatrick JP. Patterns of Failure as a Function of Clinical Target Volumes in Patients With GBM Treated With Radiation Therapy (RT), Temozolomide, and Bevacizumab International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.694 |
0.317 |
|
| 2011 |
Cuneo KC, Cabrera AR, Sampson JH, Allen KJ, Vredenburgh JJ, Peters K, Chang Z, Herndon JE, Desjardins A, Reardon DA, Kirkpatrick J. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2082. PMID 28019873 DOI: 10.1200/jco.2011.29.15_suppl.2082 |
0.3 |
|
| 2011 |
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157 |
0.328 |
|
| 2011 |
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103: 371-9. PMID 20853132 DOI: 10.1007/S11060-010-0403-6 |
0.429 |
|
| 2011 |
Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Concurrent bevacizumab and radiosurgery for recurrent malignant glioma: toxicity results from a prospective pilot study F1000research. 2. DOI: 10.7490/F1000Research.1089492.1 |
0.411 |
|
| 2011 |
Cuneo KC, Cabrera AR, Sampson J, Allen K, Duffy E, Vredenburgh JJ, Peters KB, Chang Z, Desjardins A, Kirkpatrick JP. Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.330 |
0.375 |
|
| 2010 |
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro-Oncology. 12: 871-81. PMID 20511192 DOI: 10.1093/Neuonc/Nop054 |
0.407 |
|
| 2010 |
Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Current Neurology and Neuroscience Reports. 10: 259-66. PMID 20424975 DOI: 10.1007/s11910-010-0111-9 |
0.309 |
|
| 2010 |
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96: 219-30. PMID 19562254 DOI: 10.1007/S11060-009-9950-0 |
0.326 |
|
| 2010 |
Oh DS, Reardon DA, Prosnitz LR, Gockerman JP, Sampson J, Kirkpatrick JP. Low-dose Whole Brain Radiotherapy followed by Radiosurgery for Primary CNS Lymphoma Achieving Partial Response to Induction Chemotherapy International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.696 |
0.33 |
|
| 2009 |
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8: 2773-9. PMID 19825799 DOI: 10.1158/1535-7163.Mct-09-0124 |
0.31 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 95: 393-400. PMID 19533023 DOI: 10.1007/S11060-009-9937-X |
0.312 |
|
| 2008 |
Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.Ccr-08-0260 |
0.416 |
|
| 2008 |
Selznick LA, Shamji MF, Fecci P, Gromeier M, Friedman AH, Sampson J. Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurgical Review. 31: 141-55; discussion 1. PMID 18259789 DOI: 10.1007/S10143-008-0121-0 |
0.39 |
|
| 2007 |
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/Jco.2007.12.2440 |
0.406 |
|
| 2006 |
Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM Journal of Clinical Oncology. 24: 2529-2529. DOI: 10.1200/Jco.2006.24.18_Suppl.2529 |
0.343 |
|
| 2004 |
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, ... ... Sampson JH, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/Jco.2004.08.110 |
0.306 |
|
| 2003 |
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809 |
0.315 |
|
| 2003 |
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/Jco.2003.01.009 |
0.305 |
|
| Show low-probability matches. |